Nrf2, but not β‐catenin, mutation represents an early event in rat hepatocarcinogenesis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Hepatocellular carcinoma (HCC) develops through a multistage process, but the nature of the molecular changes associated with the different steps, the very early ones in particular, is largely unknown. Recently, dysregulation of the NRF2/KEAP1 pathway and mutations of these genes have been observed in experimental and human tumors, suggesting their possible role in cancer development. To assess whether Nrf2/Keap1 mutations are early or late events in HCC development, we investigated their frequency in the rat Resistant Hepatocyte model, consisting of the administration of diethylnitrosamine followed by a brief exposure to 2‐acetylaminofluorene. This model enables the dissection of all stages of hepatocarcinogenesis. We found that Nrf2/Keap1 mutations were present in 71% of early preneoplastic lesions and in 78.6% and 59.3% of early and advanced HCCs, respectively. Mutations of Nrf2 were more frequent, missense, and located in the Nrf2‐Keap1 binding region. Mutations of Keap1 occurred at a much lower frequency in both preneoplastic lesions and HCCs and were mutually exclusive with those of Nrf2. Functional in vitro and in vivo studies showed that Nrf2 silencing inhibited the ability of tumorigenic rat cells to grow in soft agar and to form tumors. Unlike Nrf2 mutations, those of Ctnnb1, which are frequent in human HCC, were a later event as they appeared only in fully advanced HCCs (18.5%). Conclusion: In the Resistant Hepatocyte model of hepatocarcinogenesis the onset of Nrf2 mutations is a very early event, likely essential for the clonal expansion of preneoplastic hepatocytes to HCC, while Ctnnb1 mutations occur only at very late stages. Moreover, functional experiments demonstrate that Nrf2 is an oncogene critical for HCC progression and development. (H epatology 2015;62:851‐862)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337 · cited 1×
“Several studies have shown that many oncogenic pathways are involved in the modulation of metabolism.[28, 29] In this context, it is interesting to note that Nrf2, other than maintaining redox homeostasis in quiescent cells, is able to redirect glucose metabolism into anabolic pathways[30]; indeed, while increased Nrf…”
BackgroundKobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224 · cited 2×
“It is negatively regulated and targeted to proteosomal degradation by KEAP1.(4) It was reported in several studies that either loss of NRF2-KEAP1 interaction or point mutations in the KEAP1 or NRF2 gene are often associated with primary tumors.”
BackgroundNrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · cited 1×
“In this context, it is interesting to note that Nrf2, other than maintaining redox homeostasis in quiescent cells, is able to redirect glucose metabolism into anabolic pathways(30); indeed, while increased Nrf2 expression shifts glucose distribution toward purine nucleotide synthesis (through activation of the pentose…”
BackgroundNRF2 and cancer: the good, the bad and the importance of context
Sporn, M. B., & Liby, K. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3278 · Cited by 1,067 · cited 2×
“However, as pointed out by Sporn and Liby, whether NRF2 plays a pro- or an antitumorigenic role in premalignant lesions or early malignancy is still unclear.(2) Indeed, while, on the one hand, NRF2 can protect normal cells from oxidative stress and DNA-damaging electrophiles, on the other hand, it can confer cytoprote…”
BackgroundDysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060 · cited 14×
“Conclusion: In the Resistant Hepatocyte model of hepatocarcinogenesis the onset of Nrf2 mutations is a very early event, likely essential for the clonal expansion of preneoplastic hepatocytes to HCC, while Ctnnb1 mutations occur only at very late stages.”
BackgroundInfluentialShibata, T., Ohta, T., Tong, K. I., Kokubu, A., Odogawa, R., Tsuta, K., Asamura, H., Yamamoto, M., & Hirohashi, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806268105 · Cited by 728
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
The molecular determinants of de novo nucleotide biosynthesis in cancer cells
Tong, X., Zhao, F., & Thompson, C. B. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.01.002 · Cited by 351 · cited 1×
“Several studies have shown that many oncogenic pathways are involved in the modulation of metabolism.(28,29) In this context, it is interesting to note that Nrf2, other than maintaining redox homeostasis in quiescent cells, is able to redirect glucose metabolism into anabolic pathways(30); indeed, while increased Nrf2…”
Background
Cited by
Hayes, J. D., Dinkova-Kostova, A. T., & Tew, K. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.001 · Cited by 2,654
“Somatic mutations in NFE2L2 were also observed in approximately 60% of early and advanced hepatocellular carcinomas, respectively, suggesting that genetic activation of NRF2 is required throughout promotion and progression of liver tumorigenesis.”
BackgroundInfluentialFrom NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
The Dual Roles of NRF2 in Cancer
Menegon, S., Columbano, A., & Giordano, S. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.05.002 · Cited by 633
Self-citationUmemura, A., He, F., Taniguchi, K., Nakagawa, H., Yamachika, S., Font-Burgada, J., Zhong, Z., Subramaniam, S., Raghunandan, S., Duran, A., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.006 · Cited by 463
Rebouissou, S., Franconi, A., Calderaro, J., Letouzé, E., Imbeaud, S., Pilati, C., Nault, J., Couchy, G., Laurent, A., Balabaud, C., et al. (2016) · Hepatology · doi:10.1002/hep.28638 · Cited by 327
Metadata
- Authors
- Zavattari, P., Perra, A., Menegon, S., Kowalik, M. A., Petrelli, A., Angioni, M. M., Follenzi, A., Quagliata, L., Ledda‐Columbano, G. M., Terracciano, L., Giordano, S., & Columbano, A.
- Venue
- Hepatology
- Published
- 2015-04-22
- Volume
- 62
- Issue
- 3
- Pages
- 851-862
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W1715823723
- Cited by
- 88
- References
- 8
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nrf2, but not β‐catenin, mutation represents an early event in rat hepatocarcinogenesis. https://app.cochat.ai/papers/10.1002/hep.27790
- The paper
- Zavattari, P., Perra, A., Menegon, S., Kowalik, M. A., Petrelli, A., Angioni, M. M., Follenzi, A., Quagliata, L., Ledda‐Columbano, G. M., Terracciano, L., Giordano, S., & Columbano, A. (2015). Nrf2, but not β‐catenin, mutation represents an early event in rat hepatocarcinogenesis. Hepatology. https://doi.org/10.1002/hep.27790
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.